Safety and effectiveness of NDTx-03 for children and teens with ASD or social communication disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter trial compares NDTx-03 plus standard care to standard care alone in children and adolescents with ASD or SCD. It is randomized and evaluator-blinded to determine if the digital therapeutic can improve social situation recognition and interaction over 8 weeks. Primary outcome is the change in the K-VABS-II Adaptive Behavior Composite score from baseline to Day 42, with several secondary measures including SRS-2 and CGI scales. Participants continue their existing therapies (TAU) during the study. After Day 56, optional post-study access to NDTx-03 may be provided outside the randomized period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Children and adolescents aged 10 to 18 years.
2. Diagnosed with Autism Spectrum Disorder (ASD) or Social Communication Disorder (SCD) by the clinical judgment of a psychiatrist according to DSM-5 diagnostic criteria, based on the Autism Diagnostic Interview-Revised (ADI-R), Korean Wechsler Intelligence Scale for Children, Fifth Edition (K-WISC-V), and clinical assessment. Previously performed ADI-R and Wechsler intelligence scale results may be used; for Wechsler intelligence scales, any test type or version may be used, including K-WISC-V, WPPSI, or WAIS.
3. Full-Scale Intelligence Quotient (FSIQ) \>= 70 or General Ability Index (GAI) \>= 70 based on a Korean Wechsler intelligence scale (regardless of type or version, including K-WISC-V, WPPSI, or WAIS). Previously performed results may be used.
4. Able to use NDTx-03 installed on a smartphone, either independently or with assistance from a parent/legal guardian.
5. Able to comply with the recommended investigational device application schedule (5 times per week, 8 weeks, 40 sessions).
6. Agree not to use any medical device other than the investigational device during the clinical trial.
7. Agree that there will be no changes during the study in the regimen of medications that may significantly affect sociality. Medications being taken at screening may be continued, but total daily dose, active ingredient, and other regimen details must remain unchanged until the end-of-study visit.
8. Agree not to participate in additional Applied Behavior Analysis (ABA) treatment/rehabilitation/education or sociality-related treatment/rehabilitation/education programs during the study. Programs being received at screening may be continued, but frequency and treatment method must remain unchanged until the end-of-study visit.
9. The participant and parent (or legal guardian) voluntarily decide to participate and provide written informed consent/assent using the participant information sheet and informed consent form.
10. Willing to comply with the clinical trial protocol.

Exclusion Criteria:

1. Clinically significant behavioral problems, emotional regulation problems, psychotic symptoms, or risk of self-harm or harm to others at a level that may affect the treatment process.
2. Severe acute or chronic medical or psychiatric disease.
3. Serious trauma or surgery within 4 weeks before the screening date.
4. Other severe neurological disease or disability, such as brain lesion disorder or mental disorder/disability.
5. Currently participating in another clinical trial or participated in another clinical trial within 30 days before the screening date.
6. Less than 24 months have elapsed since the end date of application of the investigational medical device NDTx-01 (or Buddy In) as of the screening date.
7. Participation in a clinical trial of, or prior experience using, a digital therapeutic device or software-based intervention program that may affect efficacy assessments of this study, including cognitive function, attention, executive function, language, social development, social skills, behavior, or emotional regulation, within 12 months before the baseline visit.
8. Within 8 weeks before baseline, a change in the dosage or regimen of medications that may significantly affect sociality, or a change in participation in treatment/rehabilitation/education programs that may significantly affect sociality.
9. Any other case in which the investigator determines that participation is inappropriate for ethical reasons or because it may affect clinical trial results.

Where it's running

• Daegu Catholic University Medical Center
  Daegu, South Korea Recruiting
• Wonkwang University Hospital
  Iksan, South Korea Recruiting
• Asan Medical Center
  Seoul, South Korea Recruiting
• Samsung Medical Center
  Seoul, South Korea Recruiting
• The Catholic University of Korea, Seoul St. Mary's Hospital
  Seoul, South Korea Recruiting
• Korea University Guro Hospital
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Yoo Sook Joung, MD., PhD — Samsung Medical Center
• Study coordinator: SungJa Cho
• Email: sungja_cho@neudive.com
• Phone: +82-2-6959-9933

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sensory Integration and Deep Pressure Therapy for Motor Coordination in Children with ASD

  This study tests whether combining Sensory Integration Therapy with Deep Pressure Therapy can improve motor coordination and reduce repetitive behaviors in children aged 4–10 with autism.

  Recruiting Riphah International University · Rawalpindi, Punjab Province · NCT07911904

• Pupillometer screen to help identify autism in kids aged 2–4 during routine visits

  A handheld pupillometer test is being tried to see if it can help identify autism in young children during regular pediatric visits.

  Recruiting at 4 sites Schweitzer Engineering Laboratories · Lewiston, Idaho and 3 other locations · NCT07903675

• Leopard: using multi-omics to boost genetic diagnosis for neurodevelopmental disorders

  This study tests a multi-omics approach to find genetic explanations for neurodevelopmental disorders in people with moderate-to-severe intellectual disability.

  Recruiting Istituto Giannina Gaslini · Genova · NCT07884227

• Heart Rate Variability Biofeedback for Anxiety in Autistic Youth

  This study tests a wearable heart rate variability biofeedback tool to see if it helps reduce anxiety in autistic teens.

  Recruiting Phase 2 Massachusetts General Hospital · Lexington, Massachusetts · NCT07812233

• Structured Sensory-Based Occupational Therapy for Children with Autism

  This study tests a 12-week, 40-minute sensory-based occupational therapy program twice a week to see if it improves daily skills, sensory processing, movement, and eating in children aged 3-9 with autism.

  Recruiting Medipol University · Istanbul, Beykoz · NCT07789704

• Exergaming and Aerobic Exercise for Kids with Autism

  This study tests whether adding exergames or aerobic exercise to a standard program helps improve sleep, movement skills, thinking skills, and brain activity in children with autism.

  Recruiting National Taiwan University Hospital · Taipei · NCT07789457

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.